What Adicet Bio does

Adicet Bio, Inc. is a clinical-stage biotechnology company founded in 2014 and listed on NASDAQ under the ticker ACET. The company develops allogeneic ("off-the-shelf") gamma delta 1 CAR T cell therapies for B-cell mediated autoimmune diseases and cancer, leveraging the natural tissue-homing properties of gamma delta 1 T cells and engineered chimeric antigen receptors to enable immediate, patient-independent dosing without autologous manufacturing delays.

Its pipeline is anchored by prula-cel (formerly ADI-001), a CD20-directed allogeneic gamma delta CAR T candidate in Phase 1 development across multiple autoimmune indications — including lupus nephritis, systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA-associated vasculitis, and rheumatoid arthritis — and which has received FDA Fast Track Designation in three of these indications. Supporting programs include ADI-212 (armored PSMA-directed gamma delta CAR T for metastatic castration-resistant prostate cancer, IND planned for early 2026), ADI-270 (CD70-directed for solid and hematologic tumors), and ADI-925 (Chimeric Adapter gamma delta T cells targeting NKG2D ligand-expressing cancers). A May 2025 license agreement with CRISPR Therapeutics provides gene-editing capability for next-generation candidates, with a 50/50 cost-and-profit opt-in retained by CRISPR.

The company is pre-revenue with no commercialized products and no disclosed payer or partnership economics. It is financed through public equity ($100M in 2021, $98M in 2024, $80M in 2025), with operations spanning R&D in Redwood City (California), corporate headquarters in Boston (Massachusetts), and an office in Shanghai (China), and reports 101–250 employees. A 1-for-16 reverse stock split was executed on December 30, 2025 to maintain Nasdaq listing compliance, and Ra Capital Management is the largest disclosed shareholder at roughly 6.75%. Revenue generation is contingent on regulatory approval of one or more candidates, with a pivotal trial for prula-cel planned for Q2 2026 following an early-2026 FDA meeting.

Name

Adicet Bio

Legal name

Adicet Bio, Inc.

Website

https://adicetbio.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

Adicet Bio is a clinical-stage, NASDAQ-listed biotechnology company developing allogeneic gamma delta 1 CAR T cell therapies targeting B-cell mediated autoimmune diseases and cancer, with lead candidate prula-cel in Phase 1 across multiple autoimmune indications and supporting oncology programs in earlier development.

Ownership category

akta.pro rank

Product category

Cell Therapy / Immunotherapy Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

Keywords

• Allogeneic cell therapy
• Gamma delta CAR T
• Autoimmune disease therapy
• Oncology immunotherapy
• Off-the-shelf cell therapy

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical/Biotech Revenue: Adicet Bio is a clinical-stage biotechnology company and is pre-revenue. The company is developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Once therapies receive regulatory approval, revenue would be generated through product sales.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta 1 CAR T cell therapies for autoimmune diseases and cancer. Its lead candidate prula-cel (ADI-001) is a CD20-targeted allogeneic gamma delta CAR T cell therapy in Phase 1 development for lupus nephritis, SLE, systemic sclerosis, rheumatoid arthritis, and other autoimmune indications. The pipeline also includes ADI-212 (PSMA for prostate cancer), ADI-270 (CD70 for solid and hematologic tumors), and ADI-925 (NKG2D ligand targeting).

Product overview

Adicet Bio is a clinical stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company's proprietary platform engineers gamma delta 1 T cells with chimeric antigen receptors (CARs) to enable off-the-shelf treatments. The lead product is prulacabtagene leucel (prula-cel, formerly ADI-001), a CD20-targeted CAR gamma delta T cell therapy in Phase 1 development for multiple autoimmune conditions. The pipeline also includes ADI-212 (PSMA-targeted for prostate cancer), ADI-270 (CD70-targeted for solid and hematologic tumors), and ADI-925 (NKG2D ligand-targeted), with additional programs in discovery and preclinical stages anticipated to yield new INDs every 12-18 months.

Differentiator

Problem solved

Functional benefit

Products and services

• Prulacabtagene leucel (prula-cel, formerly ADI-001) First-in-class investigational allogeneic gamma delta CAR T cell therapy targeting CD20, in Phase 1 development for autoimmune indications including lupus nephritis, systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA-associated vasculitis, and rheumatoid arthritis.
• ADI-212 (PSMA CAR Gamma Delta T Cell Program) Armored allogeneic CAR gamma delta T cell therapy targeting prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer (mCRPC), featuring a potent CAR construct with three mechanisms of action designed to address tumor heterogeneity.
• ADI-270 Armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignancies.
• ADI-925 Allogeneic off-the-shelf Chimeric Adapter (CAd) gamma delta T cell therapy targeting NKG2D ligand-expressing cancers.

Quantifiable outcome

• Positive preliminary safety and efficacy data from Phase 1 trial of ADI-001 in lupus nephritis and SLE patients
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• CRISPR TherapeuticscoreTechnology or Integration · 26 May 2025License agreement with CRISPR Therapeutics for gene-editing technology. CRISPR has opt-in right to participate in a 50/50 cost and profit split for programs utilizing their technology. This partnership enables Adicet to leverage CRISPR's gene-editing capabilities in developing next-generation allogeneic gamma delta T cell therapies.

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Cabaletta Bio: Clinical-stage biotechnology company developing CAR-T cell therapies, including CD19-CAR-T candidates (e.g., CABA-201) for autoimmune diseases such as lupus and myositis. Directly comparable to Adicet's prula-cel in autoimmune CAR-T space with similar patient populations and clinical stage.
• Kyverna Therapeutics: Clinical-stage cell therapy company developing CD19 CAR-T therapies for autoimmune diseases including lupus nephritis and other B-cell-mediated conditions. Direct competitor to Adicet's prula-cel with overlapping autoimmune CAR-T focus and Phase 1/2 development stage.
• Allogene Therapeutics: Pioneering allogeneic CAR-T cell therapy company with multiple clinical-stage candidates for hematologic and solid tumors. Directly comparable to Adicet as a competing allogeneic CAR-T platform with similar off-the-shelf manufacturing approach.
• Atara Biotherapeutics: Allogeneic T-cell immunotherapy company developing off-the-shelf therapies for cancer and autoimmune diseases. Highly comparable platform approach to Adicet with allogeneic T-cell platform technology; CSO Blake Aftab previously led preclinical science at Atara.
• CRISPR Therapeutics: Leading gene-editing company developing CRISPR/Cas9-based therapies including allogeneic CAR-T candidates (CTX112) for autoimmune and oncology indications. Both partner and competitor to Adicet through gene-editing license arrangement.
• Fate Therapeutics: Clinical-stage biopharmaceutical company developing off-the-shelf, iPSC-derived cellular immunotherapies for cancer and autoimmune diseases. Comparable allogeneic, off-the-shelf cell therapy platform with similar manufacturing scalability approach to Adicet's gamma delta platform.
• Century Therapeutics: Clinical-stage biotechnology company developing allogeneic, iPSC-derived immune cell therapies for cancer and autoimmune diseases. Comparable off-the-shelf cell therapy platform with overlapping oncology and autoimmune indications.
• Caribou Biosciences: Clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies using CRISPR gene-editing technology for hematologic malignancies and autoimmune diseases. Comparable allogeneic CAR-T platform with similar technology base.

Emerging players

• Sana Biotechnology: Clinical-stage biotechnology company developing engineered cell therapies with hypoimmune technology for cancer and autoimmune diseases. Comparable cell therapy focus with novel allogeneic platform approach and autoimmune indication overlap.

Broad incumbents

• Bristol Myers Squibb: Global biopharmaceutical company with approved autologous CAR-T therapies (Breyanzi, Abecma) and broad autoimmune portfolio. Represents incumbent CAR-T commercialization expertise and potential strategic acquirer or partner for allogeneic CAR-T developers like Adicet.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/adicet-bio
• Xx.com/adicetbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds7 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adicet Bio